Cargando…
Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis
To assess the efficacy of rituximab in treatment of refractory nephrotic syndrome (NS) compared with other agents. Studies were searched from Web of Science, PubMed, and CNKI up to April 2016. The standardized mean difference or relative risk or odds ratio and 95% confidence intervals were used to a...
Autores principales: | Yin, Supei, He, Ting, Li, Yi, Wang, Jingshuang, Zeng, Wei, Tang, Sha, Zhao, Jinghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5268020/ https://www.ncbi.nlm.nih.gov/pubmed/27977574 http://dx.doi.org/10.1097/MD.0000000000005320 |
Ejemplares similares
-
Long-Term Prognosis of Adult Patients with Steroid-Dependent Minimal Change Nephrotic Syndrome Following Rituximab Treatment
por: Iwabuchi, Yuko, et al.
Publicado: (2014) -
Clinical efficacy and safety of beraprost sodium in the treatment of nephrotic syndrome: A meta-analysis
por: Yan, Peng, et al.
Publicado: (2023) -
Characterization of thromboelastography of patients with different pathological types of nephrotic syndrome
por: Lu, Chunlei, et al.
Publicado: (2020) -
Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis
por: Lu, WanJun, et al.
Publicado: (2020) -
The effectiveness of cyclosporine A for patients with steroid-resistant nephrotic syndrome: A protocol for systematic review and meta-analysis
por: Lv, Juan, et al.
Publicado: (2021)